99mTc-DMSA (V)‎ in Evaluation of Osteosarcoma : Comparative Studies with 18F-FDG PETCT in Detection of Primary and Malignant Lesions

Abstract EN

To evaluate the role of 99mTc-DMSA (V) and [18F]FDG PET-CT in management of patients with osteosarcoma, 22 patients were included in our study.

All patients underwent both 99mTc-DMSA (V) and whole-body [18F]FDG PET-CT scans within an interval of 1 week.

555–740 MBq of 99mTc-DMSA (V) was injected i.v.

the whole-body planar, SPECT images of primary site and chest were performed after 3-4 hours.

[18F]FDG PET-CT images were obtained 60 minutes after i.v.

injection of 370 MBq of F-18 FDG.

Both FDG PET-CT (mean SUVmax = 7.1) and DMSA (V) scans showed abnormal uptake at primary site in all the 22 patients (100% sensitivity for both).

Whole-body PET-CT detected metastasis in 11 pts (lung mets in 10 and lung + bone mets in 1 patient).

Whole-body planar DMSA (V) and SPECT detected bone metastasis in one patient, lung mets in 7 patients and LN in 1 patient.

HRCT of chest confirmed lung mets in 10 patients and inflammatory lesion in one patient.

7 patients positive for mets on DMSA (V) scan had higher uptake in lung lesions as compared to FDG uptake on PET-CT.

Three patients who did not show any DMSA uptake had subcentimeter lung nodule.

Resuts of both 99mTc-DMSA (V) (whole-body planar and SPECT imaging) and [18F]FDG PET-CT were comparable in evaluation of primary site lesions and metastatic lesions greater than 1 cm.

Though 99mTc-DMSA (V) had higher uptake in the lesions as compared to [18F]FDG PET-CT, the only advantage [18F]FDG PET-CT had was that it could also detect subcentimeter lesions.